Evonik's third-quarter sales year-on-year

sales rose 7 percent to 3.8 billion eurostZ4, adjusted EBITDA rose 8 percent to 692 million eurostZ42018 full-year forecast confirmedtZ4Essen, GermanyIn the third quarter of 2018, Evonik's adjusted ebitda (EBITDA) increased to EUR 692 million (compared to EUR 640 million in the same period last year)The two growth segments, nutrition and consumer chemicals, and resource efficiency, have achieved significant revenue growth, contributing to profitable growthAdjusted EBITDA margin rose to 18.2%, compared with 18% in the same period last yeartZ4
In the third quarter, sales rose to 3.8 billion euros (compared with 3.6 billion euros a year earlier), mainly due to higher pricesAdjusted net income rose 35 percent to 370 million euros, equivalent to adjusted earnings per share of 0.79 eurostZ4
"We continue to implement our established strategy Chairman Ku Leman said "We will continue to actively build our portfolio to bring innovative technologies to market and drive cultural change." "
tZ4 confirmed its full-year forecast tZ4 the full-year forecast for the first half of the year adjusted Adjusted EBITDA is expected to be between EUR 2.6 billion and EUR 2.65 billion, with sales also expected to increase slightly (compared to EUR 14.4 billion in the same period last year) At the same time, Evonik confirmed that free cash flow in 2018 will be significantly higher than in the same period last year (EUR 511 million) tZ4
　　Demand in key end markets will remain strong in the fourth quarter, especially in the two growth segments of nutrition and consumer chemicals and resource efficiency tZ4 business segment performed tZ4 Resource Efficiency segment: Sales rose 5% to EUR 1.4 billion in the third quarter Adjusted EBITDA increased 9% year-on-year to 338 million euros Adjusted EBITDA margin rose to 23.7% from 22.9% Strong demand for high-performance polymers for lightweight designanding and water-based, environmentally friendly coatings helped drive sales in the quarter tZ4
　　Nutrition and consumer chemicals segment: Sales rose 5 percent to 1.2 billion euros Adjusted EBITDA rose 13 percent to 212 million euros Adjusted EBITDA margin increased significantly to 18.2% (compared to 16.9% in the same period last year) For the amino acid business of animal nutrition, the market demand continues to be strong Personal care and medical and health businesses continue to grow strongly tZ4
　　Functional Materials Business Segment: Third quarter sales reached 1 billion euros, up 13% Year-on-year The increase in selling prices was mainly due to higher raw material costs The low water level of the Rhine has led to a reduction in traffic volumes, which has a negative impact on the movement of raw materials and goods The market demand for methyl acrylates continues to be good, especially in the coatings and automotive industries Adjusted EBITDA for the segment was EUR 172 million, unchanged from a year earlier Adjusted EBITDA margin decreased to 16.6% from 18.8% tZ4 sales rose 7% to 3.8 billion euros tZ4 Adjusted EBITDA rose 8% to 692 million euros tZ4 2018 full-year forecast confirmed tZ4 Essen, Germany In the third quarter of 2018, Evonik's adjusted ebitda (EBITDA) increased to EUR 692 million (compared to EUR 640 million in the same period last year) The two growth segments, nutrition and consumer chemicals, and resource efficiency, have achieved significant revenue growth, contributing to profitable growth Adjusted EBITDA margin rose to 18.2%, compared with 18% in the same period last year tZ4
　　In the third quarter, sales rose to 3.8 billion euros (compared with 3.6 billion euros a year earlier), mainly due to higher prices Adjusted net income rose 35 percent to 370 million euros, equivalent to adjusted earnings per share of 0.79 euros tZ4
　　"We continue to implement our established strategy Chairman Ku Leman said "We will continue to actively build our portfolio to bring innovative technologies to market and drive cultural change." "
tZ4 confirmed its full-year forecast tZ4 the full-year forecast for the first half of the year adjusted Adjusted EBITDA is expected to be between EUR 2.6 billion and EUR 2.65 billion, with sales also expected to increase slightly (compared to EUR 14.4 billion in the same period last year) At the same time, Evonik confirmed that free cash flow in 2018 will be significantly higher than in the same period last year (EUR 511 million) tZ4
　　Demand in key end markets will remain strong in the fourth quarter, especially in the two growth segments of nutrition and consumer chemicals and resource efficiency tZ4 business segment performed tZ4 Resource Efficiency segment: Sales rose 5% to EUR 1.4 billion in the third quarter Adjusted EBITDA increased 9% year-on-year to 338 million euros Adjusted EBITDA margin rose to 23.7% from 22.9% Strong demand for high-performance polymers for lightweight designanding and water-based, environmentally friendly coatings helped drive sales in the quarter tZ4
　　Nutrition and consumer chemicals segment: Sales rose 5 percent to 1.2 billion euros Adjusted EBITDA rose 13 percent to 212 million euros Adjusted EBITDA margin increased significantly to 18.2% (compared to 16.9% in the same period last year) For the amino acid business of animal nutrition, the market demand continues to be strong Personal care and medical and health businesses continue to grow strongly tZ4
　　Functional Materials Business Segment: Third quarter sales reached 1 billion euros, up 13% Year-on-year The increase in selling prices was mainly due to higher raw material costs The low water level of the Rhine has led to a reduction in traffic volumes, which has a negative impact on the movement of raw materials and goods The market demand for methyl acrylates continues to be good, especially in the coatings and automotive industries Adjusted EBITDA for the segment was EUR 172 million, unchanged from a year earlier Adjusted EBITDA margin decreased to 16.6% from 18.8% t4